A20-28z CXCR1 CAR T-cells

A20-28z CXCR1 CAR T-cells are an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target solid tumors expressing the integrin αvβ6. The CAR construct utilizes a 20-amino acid peptide ligand, A20FMDV2 (derived from the foot-and-mouth disease virus), for specific antigen recognition, coupled with a second-generation signaling domain comprising CD28 and CD3ζ (28z). To improve trafficking to the tumor microenvironment, these T-cells are engineered to co-express the chemokine receptor CXCR1, which responds to interleukin-8 (IL-8/CXCL8) secreted by many solid malignancies. While preclinical studies in the associated context indicated that a CXCR2-expressing variant showed superior migration, the CXCR1 variant was developed and tested as part of a strategy to enhance the homing and efficacy of CAR T-cells against αvβ6-positive cancers such as pancreatic ductal adenocarcinoma and ovarian cancer.

Other names

αvβ6-targeting CXCR1-co-expressing CAR T-cellsA20-28z-CXCR1A-20-28z-CXCR1A 20-28z-CXCR1